| Document Date: 2015-03-23 21:11:42
Open Document File Size: 290,01 KBShare Result on Facebook
Company GlaxoSmithKline Australia Pty Ltd / / Country Australia / / Currency USD / / IndustryTerm fluticasone product / treatment of chronic obstructive pulmonary disease / combination product / site audit / / MedicalCondition both asthma / pneumonia / COPD / chronic inflammatory condition / shortness of breath / Persistent Asthma / chronic obstructive pulmonary disease / steroiddependent asthma / BID Asthma / airway inflammation / chest tightness / cough / weeks Low Asthma / Severe Asthma / bronchoconstriction / asthma / / Organization National Prescribing Service / FDC / National Asthma Council / / Position Investigator / Minister / Restricted Benefit General / nurse / / Product fluticasone propionate / beta-2 / / ProgrammingLanguage FP / / Technology Trial Protocol / /
SocialTag |
Public Summary Document – March 2014 PBAC Meeting 5.8 FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, fluticasone furoate 100 microgram/actuation + vilanterol